Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

93.35 -4.68 (-4.77%)
Streaming Delayed Price Updated: 2:08 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Palvella Therapeutics, Inc. - Common Stock

News headline image
Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Q3 2025 Earnings Miss, Highlights Key Clinical Milestones ↗
Palvella Therapeutics reported a wider Q3 2025 loss, missing EPS estimates. Investors focus on its strong cash position and upcoming clinical trial data for its rare disease pipeline. 
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 11, 2025 ↗
 
Via Benzinga
News headline image
Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Wider Q2 2025 Loss, Stock Drops 13% Despite Clinical Progress ↗
Palvella Therapeutics (PVLA) reported a Q2 2025 net loss of $0.86 per share, missing estimates. Revenue was $0.0 as expected, with $70.4M cash on hand. Stock fell 13% pre-market despite clinical... 
Via Chartmill
News headline image
Earnings Scheduled For August 14, 2025 ↗
 
Via Benzinga
News headline image
Palvella Posts Cash Gain and Trial Wins ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 15, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 31, 2025 ↗
 
Via Benzinga
News headline image
Pavella - Undiscovered Biotechnology Stock ↗
The company focuses on developing therapies for rare genetic skin diseases, with its lead product QTORIN rapamycin in advanced clinical trials. 
Via Talk Markets
Topics Stocks / Equities
News headline image
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
This Intuitive Machines Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.